Kinnate Biopharma is a biopharmaceutical company advancing a pipeline of precision oncology therapeutics to treat patients with genomically defined vulnerabilities.
At Kinnate we design and develop selective small molecules with the mission
to provide the right drug to the right patient.
Program 1 is a first-in-class precision oncology opportunity focused on DNA damage repair mechanisms.
Program 2 is a next generation inhibitor targeting gene rearrangements with known resistance mutations.
Program 3 is a best-in-class inhibitor targeting a pathway clinically validated across all cancers.
Our team of oncology experts all have decades of experience
in successfully developing small molecule therapies.
Steve Kaldor, Ph.D.
CEO and Co-founder
View Bio >
Eric Murphy, Ph.D.
CSO and Co-founder
View Bio >
Sailash Patel, Pharm.D.
COO
View Bio >
A diverse blend of experience in pharmaceutical R&D,
business development and life sciences investing.
Steve Kaldor, Ph.D.
Fount Therapeutics
View Bio >
Eric Murphy, Ph.D.
Fount Therapeutics
View Bio >
Jim Tananbaum, MD
Foresite Capital
View Bio >
Fred Eshelman, Ph.D.
Eshelman Ventures
View Bio >
A unique pairing of world-class precision medicine oncology leaders and
clinical researchers from leading institutions.
Keith Flaherty, MD
Mass General Hospital
View Bio >
Ryan Corcoran, MD PhD
Mass General Hospital
View Bio >
Ezra Cohen, MD
Moores Cancer Center
View Bio >
Andrew Lowy, MD
Moores Cancer Center
View Bio >
New investors OrbiMed, Nextech Invest and Vida Ventures join existing investors Foresite Capital and Eshelman Ventures
Proceeds will be used to advance multiple precision oncology drug candidates into the clinic
SAN DIEGO – December 19, 2019 -- Kinnate Biopharma, Inc., a precision oncology company focused on the discovery and development of novel kinase inhibitors, announced today that the company raised $74.5M in an oversubscribed Series B financing. New investors OrbiMed, Nextech Invest Ltd., and Vida Ventures LLC participated in the round along with existing investors Foresite Capital and Eshelman Ventures.
Kinases play a crucial role in the carcinogenesis and metastases of various types of cancer, and kinase inhibition is a proven approach to addressing cancer resistance. The Kinnate team has been developing a broad portfolio of programs targeting substantial patient populations. Proceeds from the financing will be used to advance several development candidates from Kinnate’s existing programs into the clinic, and to fund new research programs. The funding will also be used to build out the Kinnate team of world-class oncology drug developers in its headquarters in San Diego.
“Our Kinnate team has worked efficiently to build a robust, homegrown portfolio of best-in-class and first-in-class drug candidates in less than 21 months from our Series A financing close. This Series B financing positions us well to mature our candidates to clinical Proof-of-Concept,” said Stephen Kaldor, Ph.D., co-founder and CEO of Kinnate.
“We are excited to expand our team here in San Diego with additional top caliber oncology talent on the strength of this funding. Furthermore, we are pleased to have precision oncology luminary Dr. Keith Flaherty, M.D., Director of Clinical Research at the Massachusetts General Hospital Cancer Center, join our Board of Directors,” commented Eric Murphy, Ph.D., co-founder and CSO of Kinnate.
In conjunction with the financing, Carl Gordon, Ph.D., CFA, Managing Partner at OrbiMed, Brett Zbar, M.D., Managing Director at Foresite Capital, and Michael Rome, Ph.D., Partner at Foresite Capital, have also joined the company’s board of directors.
“It has been a pleasure to support Kinnate since its 2018 Series A financing. We’re impressed with the team’s progress since then and are privileged to be joined by such a strong set of new Series B investors with particular depth in oncology,” said Jim Tananbaum, M.D., founder and managing director of Foresite Capital.
“For two decades, kinase inhibitors have addressed an increasing number of oncology indications. We are pleased to be working with the experienced team at Kinnate to continue this progress,” added Dr. Gordon of OrbiMed.
Kinnate Biopharma, Inc. is a precision oncology company advancing a pipeline of therapeutics to treat patients with genomically defined vulnerabilities. Kinnate’s focus is on the design and development of selective small molecules with the mission to provide the right drug to the right patient. Headquartered in San Diego, CA, the Kinnate team comprises oncology experts, each with decades of experience developing small molecule therapies. For more information, please visit www.kinnate.com.
Cindy Mesaros for Kinnate Biopharma
press@foresitecapital.com
415.413.7627
April 2018
Fount Therapeutics secures $22 million Series A financing from Foresite Capital and Eshelman Ventures. The funds will establish multiple subsidiary R&D companies to develop treatments in various therapeutic areas. The first "NewCo", Kinnate, will be focused on developing precision oncology treatments. Other companies soon to follow.